XSTO
BIOVIC B
Market cap8mUSD
Oct 09, Last price
0.30SEK
1D
1.00%
1Q
-25.74%
IPO
-97.63%
Name
Biovica International AB
Chart & performance
P/E
—
P/S
6.28
EPS
—
Div yield, %
—
Shrs. gr., 5y
50.36%
Rev. gr., 5y
45.15%
Revenues
13m
+55.24%
Net income
-70m
L-20.27%
CFO
-63m
L-26.43%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Biovica International AB (publ) operates as a biotechnology enterprise, concentrating on the development and market introduction of sophisticated blood-based biomarker tests. These diagnostic solutions aim to enhance the tracking and prediction of cancer treatment efficacy across Sweden and globally, with a significant focus on breast cancer. A key offering is DiviTum, a biomarker assay engineered to measure the activity levels of the enzyme thymidine kinase-1 within blood serum or cell cultures. The company's clientele includes oncology research centers, pharmaceutical corporations, and various collaborative organizations. Established in 2008, Biovica's main office is situated in Uppsala, Sweden.
Related entities
Subsidiaries
Biovica Services AB
Key people
Chairman of the Board · since 2019
Anders Rylander
Chief Executive Officer, Director
Chief Financial Officer
Christina Andersson
Operations Manager
Mattias Bergqvist
Vice President Marketing and Clinical Development
Gabriel Sack
Business Development Manager
Johanna Faris
Regulatory and Quality Assurance Director
Otti Bengtsson Gref
Research & Development Director · since 2020
Maria Birgitte Holmlund
Director · since 2016
Jarl Ulf Jungnelius
Director
Henrik Osvald
Director · since 2019
Director
Headquarters & legal address
Dag Hammarskjölds väg 54B
Uppsala, C 752 37
SE
Uppsala, C 752 37
SE
Address
Dag Hammarskjolds vag 54B
Uppsala, C 752 37
SE
Uppsala, C 752 37
SE
Previous name
Rönnerbol International AB
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑04 | 2025‑04 | 2024‑04 | 2023‑04 | 2022‑04 | 2021‑04 | 2020‑04 | 2019‑04 | 2018‑04 | 2017‑04 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||